Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of Sporadic Colorectal Adenomas With Celecoxib
NCT00005094Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2000
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of celecoxib oral solution in Colorectal Adenoma (CRA) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Percentage of subjects with newly detected adenomas at 3 years and Percentage of patients with adenomas, aspirin use at baseline, and covariates at 5 years. Started Mar 2000; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
Colorectal Adenoma (CRA)
Beyond the preview
Go deeper on NCT00005094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005094.